{"id":"p2y12-inhibitor-de-escalation","safety":{"commonSideEffects":[{"rate":"null","effect":"Bleeding"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Cerebrovascular accident"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:41:40.269899","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism is crucial in preventing blood clots and reducing the risk of ischemic events. P2Y12 inhibitors work by inhibiting the binding of ADP to the P2Y12 receptor on platelet surfaces, thereby reducing platelet activation and aggregation.","oneSentence":"P2Y12 inhibitors block the action of ADP on the P2Y12 receptor, preventing platelet activation and aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:13.337Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Myocardial infarction"},{"name":"Stroke prevention in atrial fibrillation"}]},"_fixedFields":["pubmed(5)"],"trialDetails":[{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90},{"nctId":"NCT07374718","phase":"NA","title":"Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-03-01","conditions":"Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)","enrollment":468},{"nctId":"NCT05577988","phase":"PHASE3","title":"Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-18","conditions":"MYOCARDIAL INFARCTION","enrollment":2468},{"nctId":"NCT06216821","phase":"NA","title":"OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time","status":"RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2024-07-02","conditions":"Acute Coronary Syndrome","enrollment":3490},{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT06648720","phase":"NA","title":"Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Ho Chi Minh City (UMC)","startDate":"2025-03-01","conditions":"Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI), Intravascular Ultrasound","enrollment":3566},{"nctId":"NCT05903976","phase":"PHASE3","title":"De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","startDate":"2023-06-12","conditions":"Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":200},{"nctId":"NCT04090281","phase":"PHASE4","title":"Implementing Precision Medicine Approaches to Guide Anti-platelet Selection","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2020-03-13","conditions":"Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"recentPublications":[{"date":"2025 Mar-Apr","pmid":"40476260","title":"EValuation of Acute and Early Phase P2Y12 Inhibitor DE-escalation After PerCutaneous Intervention (EVADE PCI).","journal":"Kansas journal of medicine"},{"date":"2025 May 2","pmid":"39537191","title":"Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.","journal":"European heart journal. Cardiovascular pharmacotherapy"},{"date":"2023 Nov 2","pmid":"37015874","title":"Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes-a substudy of the TROPICAL-ACS trial.","journal":"European heart journal. Cardiovascular pharmacotherapy"},{"date":"2022 Jun","pmid":"39077183","title":"Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope.","journal":"Reviews in cardiovascular medicine"},{"date":"2021 Sep","pmid":"34712935","title":"De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes.","journal":"CJC open"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"P2Y12 inhibitor de-escalation","genericName":"P2Y12 inhibitor de-escalation","companyName":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","companyId":"azienda-ospedaliera-universitaria-policlinico-g-martino","modality":"Small molecule","firstApprovalDate":"","aiSummary":"P2Y12 inhibitors block the action of ADP on the P2Y12 receptor, preventing platelet activation and aggregation. Used for Acute coronary syndrome, Myocardial infarction, Stroke prevention in atrial fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}